Aeglea BioTherapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Aeglea BioTherapeutics, Inc.

Aeglea BioTherapeutics, Inc. is a U.S.-based biotechnology company whose history and strategic identity have changed materially over time. The company was originally formed in Delaware in December 2013 as Aeglea BioTherapeutics Holdings, LLC, converted into a Delaware corporation in March 2015, and later went public through its IPO in 2016. Its historical headquarters were in Austin, Texas, United States. For much of its early public-company life, Aeglea was known as a clinical-stage biotech focused on enzyme therapeutics for rare metabolic diseases, with an emphasis on amino-acid metabolism and other high-unmet-need conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1636282/000156459017005137/agle-10k_20161231.htm?utm_source=openai)) From an operating standpoint, Aeglea’s legacy business model was built around human enzyme engineering and the development of drug candidates intended to reduce disease-driving metabolites in rare disorders. SEC filings describe clinical programs such as pegtarviliase for homocystinuria and pegzilarginase for arginase 1 deficiency, illustrating the company’s specialization in orphan diseases with limited treatment options. That profile placed Aeglea in the classic biotech risk bracket: long development timelines, substantial cash burn, and a high dependence on clinical and regulatory execution rather than commercial sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1636282/000095017023005705/agle-20221231.htm?utm_source=openai)) The most important recent corporate event for investors is the 2023 transaction in which Aeglea acquired Spyre Therapeutics on June 22, 2023, followed by a corporate rebrand to Spyre Therapeutics, Inc. on November 27, 2023. As a result, the listed entity that once operated as Aeglea now serves as the public vehicle for a very different pipeline centered on immunology. Recent SEC disclosures indicate development programs focused on extended half-life antibodies targeting α4β7, TL1A, and IL-23, with an emphasis on inflammatory bowel disease and related inflammatory indications. In other words, the company’s profile has shifted from rare metabolic enzyme therapeutics to an antibody-based immunology platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1636282/000119312523251664/d554720d8k.htm?utm_source=openai)) In competitive terms, the company now operates in a crowded and scientifically demanding segment of biotech. Its value proposition is tied to whether its product candidates can deliver a meaningfully better combination of efficacy, durability, and convenience than current standards of care in IBD and potentially other immune-mediated diseases. The competitive set includes larger pharmaceutical companies and specialist biotech peers pursuing similar inflammatory biology targets. The public company remains U.S.-domiciled, and the relevant U.S. listing venue is the NASDAQ market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1636282/000162828025008686/spyre-sx3shelffeb2025.htm?utm_source=openai)) Geographically, the company’s footprint has been U.S.-centric, with the legacy Austin, Texas base and a later corporate center associated with the post-merger Spyre platform in Waltham, Massachusetts. For investors in French-speaking markets, the key analytical takeaway is that this is no longer a straightforward rare-disease enzyme story; it is now a transformed clinical-stage immunology company whose catalysts are clinical readouts, regulatory milestones, and financing needs rather than current product revenue. That makes the stock highly event-driven and suitable mainly for investors comfortable with biotechnology binary risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1636282/000162828025008686/spyre-sx3shelffeb2025.htm?utm_source=openai))